Jeremy Sokolove
Chief Medical Officer Vor Biopharma
Seminars
Thursday 23rd July 2026
Upstream Targeting of B-Cell Dysregulation via BAFF/APRIL Inhibition in Generalized Myasthenia Gravis and Related Autoimmune Conditions
1:30 pm
- Discuss upstream modulation of B‑cell survival and differentiation through BAFF/APRIL inhibition as a therapeutic strategy in gMG
- Position BAFF/APRIL inhibition within the evolving gMG treatment landscape, in comparison with downstream approaches such FcRn and complement pathway blockade, to clarify how upstream B‑cell targeting may offer differentiated clinical benefits by addressing fundamental disease‑sustaining mechanisms
- Evaluate the efficacy and durability of BAFF/APRIL inhibition in gMG versusestablished mechanisms, assessing effects on clinical outcomes, B-cell homeostasis, immunoglobulin dynamics, and infection risk
